Andrew Reeves


Andrew ReevesAndrew Reeves Ph.D. is a registered patent agent and accomplished biotechnologist who also brings a broad background in specialty chemicals and related analytics.  His fields of R&D project activity include pharmaceutical, chemical and cleantech.  Andrew’s technical work emphasized the use of classical and cutting-edge metabolic and genetic engineering strategies to improve the productivity of diverse microbial biocatalysts for making industrial chemicals and pharmaceuticals.   For more than 20 years, Dr. Reeves contributed to innovative R&D work, in roles from Principal Scientist to Technical Director, where he managed groups of scientists on complex industrial fermentation and biochemical engineering projects.  Throughout his career Dr. Reeves has been directly involved with capturing innovation and has been an inventor or co-inventor on 13 issued patents and 7 pending patent applications.

Dr. Reeves obtained his M.S. and Ph.D. degrees in Microbiology from the University of Illinois at Urbana-Champaign. After graduation, he worked at Abbott Laboratories in the Microbial Strain and Fermentation Research department, where he pioneered the use of advanced molecular biology techniques on key microbial biocatalysts to improve antibiotic production on a commercial scale.

Prior to joining SpencePC, Dr. Reeves was Director of Strain Development and Advisor at Coskata, Inc., a cleantech biofuels start-up company.  There, he was involved in leading and advising projects in bioinformatics, molecular biology, molecular diagnostics, molecular genetics, and protein biochemistry areas across a variety of functional groups (New Technology, Molecular Genetics and Strain Development). He was also heavily engaged in many chemical engineering and operations projects including upstream, instream and downstream processes for large-scale production of bioethanol and specialty chemicals via fermentation. These activities included, demonstration of plant-scale production analytics (GC, HPLC and MS data) and implementation of bioanalytical assays for large-scale plant commercial operations. At Coskata, in close coordination with the Chief Patent Counsel, Dr. Reeves was heavily involved in myriad intellectual property portfolio activities.  These included the generation of numerous invention disclosures, drafting of many biotechnology patent applications, rendering of opinions and responses to office actions, and monitoring of the company’s IP portfolio.

Prior to Coskata, Dr. Reeves worked at a boutique start-up genetic engineering company involved in generating novel microbial biocatalysts for the production of important pharmaceuticals and nutriceuticals including antibiotics, immunosuppressants, and anti-cancer compounds.  There, he was instrumental in the development of the patented FermachannelingR technology.


  • Ph.D., Microbiology, University of Illinois-Urbana-Champaign, 1996
  • M.S., Microbiology, University of Illinois-Urbana-Champaign, 1993
  • B.A., Biology, Queens College, 1991


  • United States Patent and Trademark Office, Registration No. 75,675


  • US Patent 9,464,302 | Methods for sustaining the viability of acetogens during a decrease or cessation of syngas flow.
  • US Patent 9,428,755 | Use of novel methyltransferases for generating novel strains.
  • US Patent 9,284,528 | Genes encoding key catalyzing mechanisms for ethanol production from syngas fermentation.
  • US Patent 9,045,760 | Genes encoding key catalyzing mechanisms for ethanol production from syngas fermentation.
  • US patent 9,045,758 | Use of novel methyltransferases for generating novel strains.
  • US patent 9,040,268 | Method for controlling undesirable byproducts formation caused by contaminating organisms in the production of ethanol from syngas.
  • US Patent 9,034,617 | Processes for the anaerobic bioconversion of syngas to oxygenated organic compounds with in situ protection from hydrogen cyanide.
  • US patent 8,987,431 | Essential genes encoding conserved metabolic pathway function in autotrophic solventogenic Clostridial species.
  • US patent 8,628,943 | Genes encoding key catalyzing mechanisms for ethanol production from syngas fermentation.
  • US patent 8,551,746 | Method for controlling undesirable by-products formation caused by contaminating organisms in the production of ethanol from syngas.
  • US patent 8,039,239 | Recombinant microorganisms having modified production of alcohols and acids.
  • US patent 7,638,306 | Process of increasing cellular production of biologically active compounds.


  • Mark Weber, Andrew R. Reeves, William H. Cernota, and Roy K. Wesley. 2016. Application of in vitro transposon mutagenesis to erythromycin strain improvement in Saccharopolyspora erythraea. In: Methods Mol. Biol. in vitro mutagenesis. Vol. 1498: 257-271. Humana Press. Editor: Andrew Reeves.
  • Reeves, AR and JM Weber. 2012. Metabolic engineering of antibiotic-producing actinomycetes using in vitro transposon mutagenesis. Invited chapter for Methods in Molecular Biology In: Methods Mol. Biol. Microbial Metabolic Engineering. Vol. 834: 153-175. Humana Press. Editor: Qiong Cheng.
  • Reeves AR, Brikun IA, Cernota WH, Leach BI, Gonzalez MC, Weber JM. Engineering of the methylmalonyl-CoA metabolite node in Saccharopolyspora erythraea for increased erythromycin production.  Metab. Eng. 9(3):293-303.
  • Reeves AR, IA Brikun, WH Cernota, BI Leach, MC Gonzalez, JM Weber. Effects of methylmalonyl-CoA mutase gene knockouts on erythromycin production in carbohydrate-based and oil-based fermentations of Saccharopolyspora erythraea.  J Ind Microbiol Biotechnol. 2006 Jul; 33(7):600-609.
  • Reeves, AR, WH Cernota, IA Brikun, RK Wesley and JM. Weber.  Engineering precursor flow for increased erythromycin production in Aeromicrobium erythreum. Metab. Eng.  6: 300-312.
  • Reeves, AR, G-RWang, and AA Salyers. 1997. Characterization of four outer membrane proteins that play a role in utilization of starch by Bacteroides thetaiotaomicron Bacteriol. 179: 643-649.
  • Reeves, AR, JN D’Elia, J Frias, and AA. Salyers.   A Bacteroides thetaiotaomicron outer membrane protein essential for growth on maltooligosaccharides and starch.  J. Bacteriol.  178: 823-830.
  • Cheng, Q, MC Yu, AR Reeves, and AA Salyers.   Identification and characterization of a Bacteroides thetaiotaomicron gene, csuF, which is essential for growth on chondroitin sulfate.  J. Bacteriol. 177: 3721-3727.


« Back to Attorneys Page